NCT06401343

Use of SGLT2i in noHCM With HFpEF

Sodium-dependent Glucose Transporters 2 Inhibitor in Nonobstructive Hypertrophic Cardiomyoapthy Patients With Heart Failure With Preserved Ejection Fraction: a Prospective, Multi-center,Open-lable,Randomized Controlled Trial

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 94 (estimated)
• Sponsor: China National Center for Cardiovascular Diseases · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the impact of Sodium-dependent glucose transporters 2 inhibitor Empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of nonobstructive HCM patients with HFpEF.

Conditions

• Hypertrophic Cardiomyopathy
• Heart Failure With Preserved Ejection Fraction

Interventions

Type	Name	Description
DRUG	Empagliflozin 10 MG	Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.

Timeline

• Start date: 2022-08-01
• Primary completion: 2024-08-01
• Completion: 2025-08-01
• First posted: 2024-05-06
• Last updated: 2024-05-06

Locations

1 site across 1 country: China